BioLineRx Discloses Abstract On Pilot Study Data From Phase 2 Combination Clinical Trial Evaluating Motixafortide In First-Line Pancreatic Cancer At American Society of Clinical Oncology 2024 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
BioLineRx disclosed promising data from a Phase 2 clinical trial evaluating Motixafortide in first-line pancreatic cancer at the ASCO 2024 Annual Meeting. The study showed significant increases in CD8+ T-cell density and high rates of partial response and disease control among patients.
May 24, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioLineRx's Phase 2 trial data for Motixafortide in pancreatic cancer showed significant increases in CD8+ T-cell density and high rates of partial response and disease control, which could positively impact the stock price.
The positive clinical trial results, including significant increases in CD8+ T-cell density and high rates of partial response and disease control, suggest that Motixafortide could be an effective treatment for pancreatic cancer. This could lead to increased investor confidence and a potential rise in BioLineRx's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100